HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on UroGen Pharma (NASDAQ:URGN) and raised the price target from $54 to $60.
June 14, 2024 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on UroGen Pharma and raised the price target from $54 to $60, indicating strong confidence in the company's future performance.
The raised price target from $54 to $60 by HC Wainwright & Co. suggests increased confidence in UroGen Pharma's future performance. This positive analyst rating is likely to boost investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100